Choose Your Country or Region

TEAD

Isoform-selective Products

TEAD2 TEAD4

TEAD Products

All (13)
TEAD Inhibitors (13)
New TEAD Products

Catalog No.	Product Name	Information	Product Use Citations
S1786	Verteporfin	Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.	Acta Pharm Sin B, 2024, 14(3):1222-1240 Bone Res, 2024, 12(1):12 Cancer Lett, 2024, 587:216692
S8661	CA3 (CIL56)	CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS).	Cell Rep, 2024, 43(4):114003 BMC Cancer, 2024, 24(1):587 FEBS Open Bio, 2024, 10.1002/2211-5463.13901
S8164	YAP-TEAD Inhibitor 1 (Peptide 17)	YAP-TEAD Inhibitor 1 (Peptide 17) is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM.	Development, 2024, 151(6)dev201621 J Cell Mol Med, 2023, 27(21):3217-3234 J Cancer, 2023, 14(13):2562-2573
S8554	Super-TDU	Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.	Matrix Biol, 2024, S0945-053X(24)00107-0 Gut Microbes, 2023, 15(1):2192501 Cell Death Discov, 2023, 9(1):424
S8951	TED-347	TED-347 is a potent, irreversible, covalent and allosteric inhibitor of the TEAD⋅Yap protein-protein interaction. TED-347 inhibits TEAD4⋅Yap1 protein-protein interaction with an apparent EC50 of 5.9 μM.	Aging Cell, 2023, e13913. Sci Adv, 2023, 9(28):eadf9460 Sci Adv, 2023, 9(28):eadf9460
S9735	MGH-CP1	MGH-CP1 is a potent and selective inhibitor of transcriptional enhanced associate domain (TEAD) palmitoylation. MGH-CP1 exhibits dose-dependent and potent inhibition of TEAD2/4 auto-palmitoylation in vitro with IC50 of 710 nM and 672 nM, respectively.	EMBO Rep, 2024, 25(9):4033-4061 Sci Adv, 2023, 9(1):eadd0960 Sci Adv, 2023, 9(28):eadf9460
S8950	MYF-01-37	MYF-01-37 is a novel covalent inhibitor of TEAD targeting Cys380 when incubated with the TEAD2 protein.	Exp Dermatol, 2022, 31(10):1477-1499
E1483	IK-930	IK-930 is a selective, small-molecule inhibitor of TEAD that prevents palmitate binding and thereby disrupts aberrant TEAD-dependent transcription. IK-930 demonstrates antitumor activity in mouse xenograft models with Hippo pathway genetic alterations.
E1329	K-975	K-975 is a potent, selective and orally active TEAD inhibitor that directly inhibits YAP/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma.	Nat Commun, 2024, 15(1):8159 iScience, 2024, 27(3):109247
E4655^New	VT104	VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects.
E1599	VT107	VT107 is an enantiomer analogous to VT10 and is a potent inhibitor of pan-TEAD auto-palmitoylation with IC50 of 4.93 nM that blocks TEAD-mediated gene transcription by preventing its association with YAP/TAZ.	Mol Oncol, 2024, 10.1002/1878-0261.13749
E1598	VT103	VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation with anti-proliferative and anti-tumor activity. It also inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation and disrupts interaction between YAP/TAZ and TEAD.
E1884^New	HC-258	HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.
S1786	Verteporfin	Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.	Acta Pharm Sin B, 2024, 14(3):1222-1240 Bone Res, 2024, 12(1):12 Cancer Lett, 2024, 587:216692
S8661	CA3 (CIL56)	CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS).	Cell Rep, 2024, 43(4):114003 BMC Cancer, 2024, 24(1):587 FEBS Open Bio, 2024, 10.1002/2211-5463.13901
S8164	YAP-TEAD Inhibitor 1 (Peptide 17)	YAP-TEAD Inhibitor 1 (Peptide 17) is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM.	Development, 2024, 151(6)dev201621 J Cell Mol Med, 2023, 27(21):3217-3234 J Cancer, 2023, 14(13):2562-2573
S8554	Super-TDU	Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.	Matrix Biol, 2024, S0945-053X(24)00107-0 Gut Microbes, 2023, 15(1):2192501 Cell Death Discov, 2023, 9(1):424
S8951	TED-347	TED-347 is a potent, irreversible, covalent and allosteric inhibitor of the TEAD⋅Yap protein-protein interaction. TED-347 inhibits TEAD4⋅Yap1 protein-protein interaction with an apparent EC50 of 5.9 μM.	Aging Cell, 2023, e13913. Sci Adv, 2023, 9(28):eadf9460 Sci Adv, 2023, 9(28):eadf9460
S9735	MGH-CP1	MGH-CP1 is a potent and selective inhibitor of transcriptional enhanced associate domain (TEAD) palmitoylation. MGH-CP1 exhibits dose-dependent and potent inhibition of TEAD2/4 auto-palmitoylation in vitro with IC50 of 710 nM and 672 nM, respectively.	EMBO Rep, 2024, 25(9):4033-4061 Sci Adv, 2023, 9(1):eadd0960 Sci Adv, 2023, 9(28):eadf9460
S8950	MYF-01-37	MYF-01-37 is a novel covalent inhibitor of TEAD targeting Cys380 when incubated with the TEAD2 protein.	Exp Dermatol, 2022, 31(10):1477-1499
E1483	IK-930	IK-930 is a selective, small-molecule inhibitor of TEAD that prevents palmitate binding and thereby disrupts aberrant TEAD-dependent transcription. IK-930 demonstrates antitumor activity in mouse xenograft models with Hippo pathway genetic alterations.
E1329	K-975	K-975 is a potent, selective and orally active TEAD inhibitor that directly inhibits YAP/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma.	Nat Commun, 2024, 15(1):8159 iScience, 2024, 27(3):109247
E4655^New	VT104	VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects.
E1599	VT107	VT107 is an enantiomer analogous to VT10 and is a potent inhibitor of pan-TEAD auto-palmitoylation with IC50 of 4.93 nM that blocks TEAD-mediated gene transcription by preventing its association with YAP/TAZ.	Mol Oncol, 2024, 10.1002/1878-0261.13749
E1598	VT103	VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation with anti-proliferative and anti-tumor activity. It also inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation and disrupts interaction between YAP/TAZ and TEAD.
E1884^New	HC-258	HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.
E4655^New	VT104	VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects.
E1884^New	HC-258	HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.

Choose Selective TEAD Inhibitors